Fatty acids metabolic reprogramming and tumor microenvironment in pancreatic cancer: targeting pathways Authors: Bassant Ehab, Ekram Saleh Published: 2026 ABSTRACT AbstractPancreatic ductal adenocarcinoma (PDAC) represents a highly aggressive form of pancreatic cancer. It is distinguished by a profound metabolic plasticity that supports its survival in a hypoxic and nutrient deprived microenvironment. Among the metabolic pathways altered in PDAC, fatty acid metabolism including synthesis, uptake, storage and β-oxidation serves as a key metabolic process that supports tumor growth, progression, and therapeutic resistance. This review discusses emerging evidence on fatty acid metabolic reprogramming and its relevance to the development and progression of pancreatic ductal adenocarcinoma. Key dysregulated enzymes as well as critical metabolic regulators are highlighted. Also, we discuss how genetic alterations drive lipogenic and oxidative pathways to sustain proliferation, redox balance, and adaptation to metabolic stress. Additionally, this review integrates current evidence to illustrate how the tumor microenvironment influences enhancing lipid availability and promoting metabolic symbiosis. Finally, this review outlines current pharmacological approaches that interfere with fatty acid metabolism, emphasizing lipid metabolism as a promising potential intervention strategy to inhibit tumor growth and sensitize cancer cells to existing treatments.Graphical abstract Keywords: Fatty acids, Metabolism, Reprogramming, Lipogenesis, Tumor microenvironment, Targeted therapy, Pancreatic cancer Introduction Pancreatic cancer ranks among the most fatal malignancies worldwide and represents a major contributor to cancer related mortality, particularly in developed nations. Based on their cellular origin, pancreatic tumors are broadly classified into exocrine and endocrine neoplasms. Endocrine pancreatic cancers arise from hormone producing cells responsible for regulating glucose homeostasis through the secretion of insulin, glucagon, and other peptides. These tumors are collectively referred to as pancreatic neuroendocrine tumors (NETs), also known as islet cell tumors. NETs are much less common than pancreatic exocrine tumors making up less than 5 percent of all pancreatic cancer cases. The second type, pancreatic exocrine tumors, include pancreatic adenocarcinoma which constitutes the most common type of pancreatic cancers (> 90%) and mainly impacts exocrine glands that are responsible for secreting enzymes for carbohydrates, fats and proteins break down in the duodenum [1]. As the most prevalent subtype of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) is characterized by aggressive disease behavior and one of the lowest reported five-year survival rates, approaching 9% [2]. This type of pancreatic cancer is highly malignant and invasive with few signs appearing prior to reaching its severe stage. Consequently, patients are not treated at the early stages and they are diagnosed with advanced or metastatic disease [3]. Cigarette smoking [4, 5], diabetes mellitus [6] and obesity [6, 7] are known risk factors for PDAC, as well as the genetic changes and aging. Therapeutic options for pancreatic cancer remain limited, primarily including surgery, chemotherapy, and radiotherapy, only a small percentage of PDAC cases are surgically treated owing to the lack of screening techniques and the late appearance of the symptoms [8]. In addition, the late stages of PDAC are resistant towards the chemotherapy because of the broad diversity of genetic mutations that leads to the poor survival rate [9]. Recently, the resistance of PDAC to the different treatment modalities is attributed to the alteration of metabolic processes at the cellular level, which is one of the key elements of the hallmarks of cancer. Cancer cells, unlike most of the quiescent cells, have different metabolic profiles that promote and support the tumor initiation, growth and invasion [10]. In recent years, increasing evidence has shown that fatty acids metabolism supports tumorigenesis and disease progression as well as treatment resistance through enhanced fatty acids synthesis, storage, and catabolism. Consequently, a deeper insight into fatty acid metabolic reprogramming networks may offer innovative and promising approaches for early detection, prognostic evaluation, and targeted therapeutic interventions in pancreatic cancer. In this review, we aim to elucidate the alterations in fatty acid metabolism that drive pancreatic cancer progression, alongside the pharmacological inhibitors targeting these pathways. Additionally, we will examine the crosstalk between the pancreatic tumor microenvironment and fatty acid metabolic reprogramming. Materials and methods Search strategy and selection criteria Relevant literature was identified through searches of PubMed, Scopus, and Web of Science databases for studies published between 2010 and 2026. The search focused on keywords related to fatty acid metabolism, metabolic reprogramming, targeted therapy, and pancreatic cancer. Retrieved articles were screened based on title and abstract relevance, followed by full-text evaluation of selected studies. Priority was given to English language original research articles and relevant experimental studies involving cellular or animal models. Fatty acids metabolism Fatty acid synthesis Fatty acid synthesis is a tightly regulated anabolic process responsible for generating long chain saturated fatty acids, primarily palmitate (C16:0), from acetyl CoA and malonyl CoA in the cytosol. In pancreatic ductal adenocarcinoma (PDAC), this pathway is frequently upregulated to support rapid proliferation, membrane biogenesis, and redox balance [11, 12]. The process initiates with the transport of citrate from the mitochondria to the cytosol, where ATP citrate lyase (ACLY) catalyzes its cleavage into acetyl CoA and oxaloacetate. This reaction links mitochondrial carbon flux to cytosolic lipid synthesis. Acetyl CoA is carboxylated to malonyl CoA by acetyl CoA carboxylase (ACC), the rate limiting enzyme in the pathway. Following malonyl CoA generation, the elongation process is catalyzed by fatty acid synthase (FASN), a multifunctional enzymatic complex composed of seven catalytic domains. The enzyme sequentially condenses acetyl CoA and malonyl CoA to produce β-ketoacyl intermediates, which undergo reduction, dehydration, and a second reduction to yield a fully saturated acyl chain [11]. Each elongation cycle requires two molecules of NADPH, primarily supplied by the pentose phosphate pathway and the malic enzyme reaction [12]. The synthesis continues iteratively until a 16-carbon palmitate molecule is formed and released by the thioesterase domain of FASN. Palmitate can then be elongated or desaturated in the endoplasmic reticulum to generate other lipid species (Fig. 1). Fatty acid synthesis and metabolic reprogramming in PDAC. Glucose enters the cell via the glucose transporter GLUT1 and is converted to pyruvate through glycolysis. Within mitochondria, pyruvate is converted to acetyl CoA, which enters the tricarboxylic acid (TCA) cycle to produce citrate. Citrate is then exported to the cytoplasm, where ATP citrate lyase (ACLY) converts it into cytosolic acetyl CoA the primary substrate for de novo fatty acid synthesis. Alternatively, acetate imported via monocarboxylate transporters (MCTs) is converted to acetyl CoA by acetyl CoA synthetase (ACSS). Acetyl CoA carboxylase (ACC) catalyzes the formation of malonyl CoA, the rate limiting step in lipogenesis. Fatty acid synthase (FASN) then converts malonyl CoA into palmitic acid, which is further desaturated by stearoyl CoA desaturase (SCD) in the endoplasmic reticulum (ER) to generate monounsaturated fatty acids (MUFA). In PDAC, Lipogenic enzymes (ACLY, ACSS, ACC, FASN, and SCD) are transcriptionally upregulated by the AKT, KRAS, c-MYC and HER2 signaling cascades and the sterol regulatory element binding protein 1c (SREBP-1c) pathway. In contrast, the STK11–AMPK axis negatively regulates lipogenesis by phosphorylating and inhibiting ACC Fatty acid catabolism through β-Oxidation pathway Fatty acid degradation, predominantly occurring via the mitochondrial β-oxidation pathway, is a crucial metabolic route for energy production, particularly under conditions of nutrient stress. In contrast to the historically dominant view that cancer cells rely predominantly on glycolysis (the Warburg effect), accumulating evidence suggests that PDAC can exploit fatty acid oxidation (FAO) as a metabolic adaptation to sustain survival under hypoxic and nutrient deprived conditions [13]. The β-oxidation pathway begins with the activation of long chain fatty acids in the cytoplasm by acyl CoA synthetases, producing fatty acyl CoA. This is followed by transport into the mitochondria via the carnitine shuttle, where carnitine palmitoyl transferase I (CPT1A) catalyzes the conversion of fatty acyl CoA to acyl carnitine, allowing mitochondrial entry [14]. Inside the mitochondrial matrix, carnitine palmitoyl transferase 2 (CPT2) reconverts acyl carnitine back to acyl CoA, which undergoes sequential cycles of β-oxidation. Each cycle removes two carbon units from the fatty acid chain, generating acetyl CoA, NADH, and FADH₂, which feed into the TCA cycle and electron transport chain to support oxidative phosphorylation [15] (Fig. 2). Fatty acid catabolism through β-oxidation. Fatty acids are first activated in the cytosol to form fatty acyl CoA at the expense of ATP. The activated fatty acyl CoA is transported into the mitochondrial matrix via the carnitine shuttle involving CPT-I, translocase, and CPT-II. Inside the matrix, fatty acyl CoA undergoes repetitive cycles of β-oxidation consisting of four sequential reactions: [1] oxidation by acyl CoA dehydrogenase producing FADH₂, [2] hydration by enoyl CoA hydratase, [3] oxidation by β-hydroxyacyl CoA dehydrogenase generating NADH + H, and [4] thiolytic cleavage by β-ketothiolase releasing acetyl CoA and a shortened fatty acyl CoA. The shortened acyl CoA re-enters the cycle until complete conversion into acetyl CoA units, which subsequently enter the TCA cycle for ATP production. KRAS enhances mitochondrial β-oxidation through AMPK activation which increases the expression of CPT-1. On the other hand, c-MYC indirectly suppresses FAO by downregulating the expression of CPT-1 and inhibiting AMPK signaling It is often believed that the development of cancer is caused by the accumulation of genetic changes that activate cellular oncogenes and deactivate tumor suppressor genes [16]. There are many oncogenes and tumor suppressor genes that reprogramming the metabolism of lipids in pancreatic cells. The development of PDAC is frequently driven by the accumulation of genetic mutations that activate oncogenes and suppress tumor suppressor genes. These genetic alterations contribute not only to cell proliferation and survival but also to metabolic reprogramming, particularly in lipid metabolism and fatty acid β-oxidation [17]. Upstream Signaling involved in fatty acid metabolic reprogramming in PDAC 1KRAS One of the most frequently mutated oncogenes in pancreatic ductal adenocarcinoma (PDAC) is KRAS, with mutations present in over 90% of cases. Beyond its well-established role in driving cell proliferation and survival, oncogenic KRAS plays a pivotal role in metabolic reprogramming, including fatty acid metabolism. Oncogenic KRAS enhances de novo lipogenesis by upregulating the expression of key lipogenic enzymes [18]. It stimulates the transcription factor SREBP1, which in turn upregulates FASN and ACC, thus promoting fatty acid synthesis necessary for membrane biosynthesis and energy storage [19]. This lipogenic program supports the increased proliferation demands of KRAS mutant pancreatic tumor cells. Moreover, KRAS signaling promotes the expression of ACLY (ATP citrate lyase), which converts citrate to acetyl CoA, a critical precursor for fatty acid synthesis. This metabolic rerouting ensures a steady supply of lipid building blocks for tumor growth [20] (Fig. 1). KRAS mutations have also been associated with increased uptake of exogenous fatty acids. For instance, KRAS driven upregulation of CD36, a fatty acid translocase, enhances lipid uptake from the tumor microenvironment, further supporting cancer cell survival under metabolic stress [21]. Additionally, KRAS has been shown to enhance mitochondrial β-oxidation under nutrient limited conditions. Through AMPK activation, KRAS mutant cells can increase the expression of fatty acid oxidation genes such as CPT1A, enabling metabolic flexibility and adaptation to hypoxia and glucose deprivation [22]. AKT The AKT signaling pathway plays a critical role in metabolic reprogramming of cancer cells, including PDAC. Aberrant activation of the PI3K/AKT/mTOR axis, frequently observed in PDAC, contributes to enhanced anabolic metabolism, particularly de novo lipogenesis [23]. AKT1, the most widely studied isoform in pancreatic cancer, promotes lipogenesis by activating the transcription factor SREBP1. Activated AKT facilitates SREBP1 cleavage and translocation into the nucleus, where it drives the expression of key lipogenic enzymes such as FASN, ACC, and SCD1 [24]. This upregulation provides tumor cells with the necessary lipid components for membrane biosynthesis, proliferation, and redox balance. In addition, AKT enhances the expression and activity of ACLY, which converts mitochondrial citrate into cytosolic acetyl CoA, the key substrate for fatty acid synthesis. This AKT dependent pathway ensures a consistent supply of acetyl CoA even under nutrient stress [25] (Fig. 1). Recent studies also indicate that AKT activation may indirectly suppress fatty acid β-oxidation by inhibiting AMPK, thereby shifting the balance toward lipid accumulation rather than catabolism, which favors tumor growth [26]. Moreover, AKT mediated phosphorylation of ACC reduces its inhibition, further promoting malonyl CoA production and subsequent fatty acid synthesis. c-erbB2 (HER2/ERBB2) While overexpression of c-erbB2 (HER2/ERBB2) is more commonly associated with breast and gastric cancers, emerging evidence suggests it may also contribute to metabolic reprogramming in a subset of pancreatic cancers, particularly in tumors with HER2 amplification or overactivity of the ERBB signaling axis. HER2 is a member of the epidermal growth factor receptor (EGFR) family and functions as a potent activator of downstream signaling cascades such as the PI3K/AKT/mTOR and RAS/MAPK pathways. Through these pathways, HER2 overactivation indirectly drives metabolic shifts, including enhanced fatty acid synthesis. One of the key mechanisms by which HER2 promotes lipogenesis is through activation of SREBP1, a master regulator of lipid biosynthesis. HER2 signaling induces SREBP1 maturation and nuclear translocation, leading to transcriptional upregulation of enzymes such as FASN, ACC, and SCD1, thereby promoting de novo fatty acid synthesis [27]. Additionally, HER2 signaling may elevate the expression of ACLY, thereby increasing the production of acetyl CoA for fatty acid synthesis (Fig. 1). In some pancreatic cancers, co-activation of HER2 and KRAS has been observed to synergistically enhance lipogenic gene expression and support tumor growth, suggesting that HER2 may serve as a cooperating oncogenic driver in metabolic reprogramming [28]. c-MYC c-MYC, a transcription factor encoded by the MYC oncogene, is a central regulator of cellular growth and metabolism. Its overexpression is a hallmark of many malignancies, including PDAC and is strongly associated with metabolic reprogramming to support rapid proliferation [29]. In the context of lipid metabolism, c-MYC enhances de novo fatty acid synthesis by transcriptionally upregulating key enzymes such as FASN, ACC, and ACLY [30]. Through this mechanism, MYC drives the production of fatty acids required for membrane biosynthesis and energy storage, supporting the anabolic needs of proliferating cancer cells. Furthermore, c-MYC has been shown to activate SREBP1, a master transcriptional regulator of lipid biosynthesis, creating a feed forward loop that amplifies lipogenic enzyme expression [31] (Fig. 1). This MYC–SREBP1 axis is particularly important under conditions of metabolic stress, allowing tumor cells to maintain membrane integrity and survive nutrient deprivation. c-MYC also indirectly suppresses fatty acid oxidation (FAO) by downregulating the expression of CPT1A and inhibiting AMPK signaling, thereby favoring lipid accumulation over catabolism [32] (Fig. 2). This metabolic shift not only supports membrane synthesis but also prevents excessive reactive oxygen species (ROS) production from FAO, which could otherwise lead to ferroptosis or oxidative stress-induced cell death. TP53 TP53, one of the most frequently mutated tumor suppressor genes in PDAC, plays a crucial role in regulating cellular metabolism, including fatty acid homeostasis. Mutant TP53 has been shown to cooperate with SREBPs to increase lipogenic gene expression, thereby supporting membrane synthesis, tumor cell proliferation, and resistance to metabolic stress [33, 34] (Fig. 1). Moreover, mutant p53 contributes to lipid droplet accumulation and reshaping of cellular lipid composition, which can protect cancer cells from ferroptosis and enhance adaptation to nutrient deprivation, a common feature of the pancreatic tumor microenvironment [35]. Overall, TP53 mutations rewire fatty acid metabolism in PDAC by removing constraints on lipogenesis and FAO regulation, facilitating tumor growth and metabolic plasticity. STK11/LKB1 STK11, also known as LKB1, is a serine/threonine kinase and a well-established tumor suppressor that exerts its effects primarily through activation of AMP activated protein kinase (AMPK). In normal cells, the LKB1–AMPK axis maintains energy homeostasis by inhibiting anabolic pathways such as fatty acid synthesis and promoting catabolic processes including fatty acid β-oxidation. In PDAC, loss or inactivation of LKB1 disrupts this energy sensing pathway, leading to unchecked lipid biosynthesis and reduced fatty acid oxidation. Specifically, LKB1 deficiency results in reduced AMPK activation, which leads to increased activity of ACC1 (acetyl CoA carboxylase 1) and FASN (fatty acid synthase), thereby enhancing de novo lipogenesis [36] (Fig. 1). Studies have also shown that LKB1 loss synergizes with oncogenic KRAS in PDAC to promote a highly anabolic metabolic phenotype, characterized by increased glucose uptake, lipogenesis, and reduced reliance on oxidative metabolism [24]. CDKN2A CDKN2A encodes for two critical tumor suppressor proteins, p16^INK4a and p14^ARF, which regulate cell cycle progression and apoptosis. Loss or mutation of CDKN2A is frequent in PDAC and contributes not only to uncontrolled proliferation but also to metabolic reprogramming, including lipid metabolism alterations [37]. Recent studies have demonstrated that loss of CDKN2A function correlates with enhanced lipogenic activity in pancreatic cancer cells. This occurs partly through the dysregulation of the RB/E2F pathway, where E2F transcription factors, when unchecked, induce expression of lipogenic genes including FASN and SCD1 [38]. Consequently, CDKN2A loss has been linked to upregulation of enzymes involved in fatty acid elongation and desaturation, contributing to the production of monounsaturated fatty acids, which play a protective role against oxidative stress and support tumor cell survival in the nutrient deprived tumor microenvironment [39]. Furthermore, CDKN2A inactivation may interact with oncogenic KRAS signaling to amplify lipogenic pathways, thereby facilitating aggressive metabolic phenotypes and chemoresistance in PDAC [40]. PTEN PTEN (phosphatase and tensin homolog) is a critical tumor suppressor gene that negatively regulates the PI3K/AKT signaling pathway, which is central to cellular metabolism and growth. Loss of PTEN function results in enhanced AKT pathway activation, promoting SREBP1 mediated transcription of genes involved in fatty acid biosynthesis and desaturation [41] (Fig. 1). This leads to increased lipid accumulation, supporting membrane biogenesis, energy storage, and generation of signaling lipids that favor pancreatic tumor progression. Furthermore, PTEN deficiency contributes to altered mitochondrial metabolism, decreasing fatty acid oxidation rates and shifting cancer cells towards an anabolic, lipogenic phenotype that facilitates survival under metabolic stress [41, 42]. In pancreatic cancer, mutations in oncogenes and tumor suppressor genes drive the dysregulation of fatty acid metabolic enzymes, contributing to metabolic reprogramming that supports rapid tumor growth and survival. Key enzymes involved in fatty acid synthesis, including FASN, ACC, and SCD1, are frequently overexpressed, thereby promoting de novo lipogenesis, altering cellular lipid composition, and facilitating tumor progression. Effector enzymes in fatty acid metabolic reprogramming in PDAC ATP Citrate Lyase (ACLY) ATP citrate lyase also known as ATP citrate synthase, a 480-kDa tetramer of 1101 amino acids, is primarily found in the cytosol and nucleus. It converts citrate to oxaloacetate and acetyl CoA, a crucial step in lipogenesis [43]. ACLY overexpression has been linked to tumor progression in numerous cancer types, notably colon cancer [43]. On the other hand, downregulation of ACLY, either genetically or pharmacologically, greatly lowers tumor cell viability and restricts proliferation, invasion, and metastasis [44]. ACLY not only contributes to lipogenesis in the cytosol, but also produces acetyl CoA in the nucleus for histone acetylation and gene transcription regulation [45]. The AKT-ACLY signaling pathway may be triggered by growth factors or oncogenic KRAS, leading to widespread histone acetylation in cancer cells, which is associated with poor prognosis and tumor growth [46]. Acetyl CoA Synthetase (ACSS) Acetyl CoA synthetases constitute a subgroup of short chain acyl CoA synthetases that generate acetyl CoA through the enzymatic activation of acetate using coenzyme A as a substrate. Three isoforms have been identified within this family ACSS1, ACSS2, and ACSS3 with distinct subcellular distributions. ACSS1 and ACSS3 are confined mainly to the mitochondrial compartment, whereas ACSS2 exhibits dynamic localization between the cytosol and the nucleus [47]. Among these enzymes, ACSS2 has emerged as the predominant isoform implicated in cancer biology. Its transcription is driven by sterol regulatory element-binding proteins (SREBPs), resulting in elevated expression across multiple tumor types, particularly in metabolically challenged environments [48]. Functional silencing of ACSS2 markedly suppresses tumor growth, underscoring the essential contribution of acetate metabolism to malignant progression [49]. In pancreatic cancer (PC), elevated ACSS2 expression facilitates increased acetate uptake to sustain lipid biosynthesis and membrane phospholipid production, particularly under metabolically stressful conditions such as hypoxia and nutrient deprivation [50]. Acetyl CoA Carboxylase (ACC) Acetyl CoA carboxylase functions as the key rate controlling enzyme in de novo fatty acid biosynthesis by catalyzing the ATP-dependent conversion of acetyl CoA into malonyl CoA. In mammals, ACC exists as two distinct isoforms, ACC1 and ACC2 [51]. ACC1, encoded by the ACACA gene, is a cytosolic enzyme predominantly expressed in lipogenic tissues and serves as a central driver of fatty acid production. Its activity is tightly regulated at multiple levels, including transcriptional control by sterol regulatory element binding proteins (SREBPs) [52], as well as posttranslational mechanisms involving phosphorylation, allosteric modulation, and protein–protein interactions [51]. In contrast, ACC2, encoded by ACACB, is primarily localized to the outer mitochondrial membrane, where it regulates fatty acid flux into β-oxidation pathways by modulating malonyl CoA availability [53]. In pancreatic cancer (PC), higher circulating triglyceride levels and increased intratumoral ACC1 expression have been associated with diminished therapeutic responses to everolimus based regimens [54]. Fatty acid Synthase (FASN) Fatty acid synthase is a central lipogenic enzyme that drives de novo fatty acid biosynthesis by catalyzing the sequential condensation of one acetyl CoA molecule with seven malonyl CoA units to generate palmitate, a 16-carbon saturated fatty acid that serves as a precursor for complex lipid species, membrane phospholipids, and protein palmitoylation processes [55]. Clinical evidence indicates that circulating FASN levels are significantly elevated in patients with pancreatic cancer (PC) and intraductal papillary mucinous neoplasia (IPMN) compared with healthy individuals [56]. At the cellular level, FASN expression is markedly enriched in pancreatic cancer stem-like cells relative to their parental counterparts [57]. From a clinical perspective, high tumoral FASN expression correlates with reduced overall survival in PC patients and is associated with diminished responsiveness to gemcitabine-based chemotherapy, the cornerstone of systemic treatment for this malignancy [58]. Tumor associated upregulation of FASN is primarily governed at the transcriptional level by sterol regulatory element binding protein 1 (SREBP1), which acts downstream of multiple oncogenic signaling cascades, including PI3K/AKT and MEK/ERK pathways [59]. Given its essential role in oncogenic KRAS driven pancreatic tumorigenesis, EGFR signaling further enhances FASN expression through ERK dependent mechanisms [60]. Stearoyl CoA Desaturase (SCD) Stearoyl CoA desaturase is an endoplasmic reticulum localized membrane bound enzyme that introduces a cis double bond at the Δ9 position of saturated fatty acyl CoAs, specifically converting stearoyl CoA (C18:0) and palmitoyl CoA (C16:0) into the monounsaturated fatty acids oleate (C18:1) and palmitoleate (C16:1), respectively. The transcription of SCD is under the regulatory control of sterol regulatory element binding proteins (SREBPs). The SCD gene family comprises five members (SCD1–SCD5), of which SCD1 and SCD5 are expressed in humans [61]. Aberrant upregulation of SCD1 has been documented across a broad spectrum of malignancies, and pharmacological or genetic inhibition of SCD1 markedly suppresses tumor formation in xenograft cancer models [62]. In the context of PC, elevated SCD1 expression has been consistently detected in both tumor tissues and pancreatic cancer cell lines [63]. Accumulating evidence indicates that SCD1 supports PC cell survival by conferring resistance to ferroptotic cell death, thereby maintaining lipid homeostasis under oncogenic stress [64]. Furthermore, recent studies have demonstrated that SCD activity is critical during the early stages of pancreatic tumorigenesis. Inhibition of SCD disrupts endoplasmic reticulum lipid balance, leading to activation of the unfolded protein response (UPR), which ultimately restrains pancreatic tumor growth [65]. Therapeutic targets in fatty acids metabolic reprogramming for pancreatic cancer The metabolic plasticity of PDAC enables tumor cells to adapt and thrive in the nutrient and oxygen deprived tumor microenvironment. This adaptability is, in part, driven by alterations in fatty acid metabolism, making lipid metabolic pathways attractive therapeutic targets. Interventions that disrupt fatty acid synthesis, uptake, and oxidation have shown promise in preclinical studies as strategies to impair tumor growth and overcome therapy resistance. One of the most studied targets is FASN, a key enzyme responsible for the de novo synthesis of palmitate from acetyl CoA and malonyl CoA. Inhibition of FASN has been demonstrated to reduce proliferation and induce apoptosis in PDAC cells, highlighting its role as a metabolic vulnerability [66]. Moreover, there are many drugs that may control lipogenic enzymes involved in pancreatic cancer by blocking the action of those lipogenic enzymes. Examples are ATP citrate lyase, acetyl CoA synthetase, stearoyl CoA desaturase 1 and acyl CoA synthetase, which could also be an effective target for cancer treatment [67]. In addition, targeting fatty acid uptake is another promising approach. The transmembrane transporter CD36 facilitates the import of exogenous fatty acids and has been implicated in metastasis and chemoresistance in pancreatic cancer models. Antibody mediated blockade or genetic silencing of CD36 reduces lipid accumulation and impairs metastatic potential [68]. Moreover, enzymes involved in FAO, such as carnitine palmitoyl transferase 1 (CPT1), are critical for maintaining energy homeostasis in PDAC cells, especially under metabolic stress. Pharmacological inhibition of CPT1 has been shown to decrease tumor cell viability and sensitize cells to chemotherapy by limiting ATP production and increasing reactive oxygen species [69]. Additionally, the acetate utilization pathway represents a novel therapeutic angle. Inhibiting acetyl CoA synthetase 2 impairs the conversion of acetate to acetyl CoA, thereby restricting lipid synthesis in hypoxic and nutrient poor environments typical of PDAC [70]. Collectively, these findings underscore the potential of combining inhibitors of fatty acid metabolism with standard chemotherapies or immune checkpoint blockade to enhance treatment efficacy. Drugs targeting lipogenic enzymes in PDAC and various types of cancer Fatty acid synthase inhibitors Cerulenin Cerulenin is a natural antibiotic that inhibits FASN by covalently binding to its active site. In PDAC cell lines, including MiaPaCa-2 and AsPC-1, cerulenin treatment reduced cell proliferation and induced apoptosis, as evidenced by increased caspase-3 activity and PARP cleavage. The effect was reversed by exogenous palmitate, indicating that the apoptotic response results from inhibition of de novo fatty acid synthesis [71]. C75 C75, a synthetic FASN inhibitor, was developed to overcome some limitations of cerulenin. It inhibits de novo fatty acid synthesis by blocking the enzymatic activity of FASN, particularly the synthesis of long chain fatty acids such as palmitate. This inhibition disrupts membrane lipid production and cellular energy homeostasis, leading to reduced cell proliferation and induction of apoptosis in cancer cells. In addition, C75 activates carnitine palmitoyltransferase-1 (CPT-1), which enhances fatty acid β-oxidation and contributes to weight loss and appetite suppression [72]. In human cancer cells and xenograft models, C75 treatment decreased viability, caused G2/M cell cycle arrest, and induced apoptosis, indicated by activation of caspases and DNA fragmentation [73]. Luteolin Luteolin, a dietary flavonoid, inhibits FASN activity and downstream oncogenic pathways. Luteolin reduced cell proliferation, migration, and invasion, while promoting apoptosis through suppression of c-Met, PI3K/Akt, and NF-κB signaling [74]. Mechanistically, luteolin suppresses FASN mediated lipogenesis and inhibits PI3K/Akt and NF-κB signaling, leading to cell cycle arrest and apoptotic cell death in multiple cancer cell lines such as PDAC, breast, colon and lung [74]. C93 C93 is a synthetic FASN inhibitor derived from bacterial FabB inhibitor analogs. C93 suppresses FASN dependent lipid biosynthesis, resulting in metabolic stress, impaired membrane synthesis and apoptosis induction in pancreatic cancer cells. In preclinical PDAC models (MiaPaCa-2 xenografts), C93 reduced tumor growth, decreased lipid synthesis, and triggered apoptosis without significant weight loss or systemic toxicity [75]. TVB-2640 Several small molecule FASN inhibitors, such as TVB-2640, are currently undergoing clinical evaluation for various cancers, including PDAC [76]. TVB-2640 selectively inhibits FASN activity, leading to suppression of de novo fatty acid synthesis, disruption of membrane lipid organization, and inhibition of PI3K/AKT/mTOR signaling pathways, ultimately reducing tumor cell survival and proliferation [77]. TVB-3166 TVB-3166 is a second generation, selective FASN inhibitor designed to overcome the toxicity observed with earlier compounds. Preclinical studies demonstrated that TVB-3166 effectively suppresses intracellular fatty acid synthesis, alters membrane lipid composition, and disrupts lipid raft dependent oncogenic signaling pathways, including the PI3K/AKT axis. The compound exhibited significant antitumor activity in PC3-TxR and DU145-TxR cell lines, supporting its role as a precursor for clinically advanced FASN targeted therapies [78]. Orlistat (repurposed FASN inhibitor) Orlistat, a drug originally approved for the treatment of obesity, has been identified as an inhibitor of the thioesterase domain of FASN. Several in vitro studies reported that orlistat suppresses tumor cell proliferation and induces apoptosis in prostate cancer cell line (PC-3). Nevertheless, its poor systemic bioavailability and lack of optimization for oncologic indications have limited its clinical utility as a FASN targeted anticancer agent [79, 80] (Fig. 3). Key enzymes and therapeutic targets in fatty acid biosynthesis in PDAC. The diagram illustrates the central steps of fatty acid biosynthesis as shown in Fig. 1. In addition, the figure also highlights the roles of ATP citrate lyase (ACLY), acetyl CoA synthetase (ACSS), and acetyl CoA carboxylase (ACC) in supplying and activating fatty acyl units. Pharmacological inhibitors included in the schematic illustrate key therapeutic entry points that can disrupt lipid anabolism in cancer cells. SB-204990 and hydroxy citrate inhibit ACLY while TOFA and Soraphen A block ACC. Cerulenin, C75, Luteolin, and C93 suppress FASN. Moreover, CVT-11127 dampens SCD, and Triacsin C represses ACSS ATP citrate lyase inhibitors SB-204990 SB-204990 is a potent ACLY inhibitor which binds to the citrate binding site, represented by Hydroxycitric acid [81]. Mechanistically, SB-204990 inhibits ACLY mediated conversion of citrate into acetyl CoA, thereby suppressing lipid biosynthesis and reducing the availability of substrates required for rapid tumor growth and membrane formation in human lung cancer cells [82]. Bempedoic Acid (ETC-1002) Bempedoic acid is an ACLY inhibitor originally developed and clinically approved for the treatment of hypercholesterolemia. The compound selectively inhibits ACLY in the liver, reducing cytosolic acetyl CoA availability for lipid synthesis. In addition to lipid synthesis inhibition, bempedoic acid reduces histone acetylation through depletion of acetyl CoA pools, thereby modulating cancer related gene expression [83]. Preclinical studies on breast and pancreatic cell lines (MDA-MB-231, MCF-7, T47D, Panc-1, MiaPaCa-2, and BxPC-3) suggest that bempedoic acid can suppress tumor cell proliferation, particularly in cancers highly dependent on de novo lipogenesis. Additionally, ACLY inhibition by bempedoic acid has been associated with reduced histone acetylation and modulation of gene expression linked to tumor progression. Despite these promising findings, its anticancer application remains largely preclinical [83]. NDI-091143 (emerging ACLY inhibitors) NDI-091143 is a recently characterized, highly selective ACLY inhibitor identified via structure-based drug design. It targets the citrate binding site of ACLY, leading to potent suppression of cytosolic acetyl CoA production. Preclinical studies on FTC-133 cell line demonstrated that NDI-091143 inhibits cancer cell proliferation, disrupts lipid synthesis, and reduces histone acetylation, highlighting the dual metabolic and epigenetic effects of ACLY inhibition. These findings suggest that NDI-091143 could serve as a promising lead compound for future ACLY targeted cancer therapies [84] (Fig. 3). Acetyl CoA carboxylase inhibitors Soraphen A Soraphen A is a potent natural inhibitor of ACC, acting allosterically to disrupt biotin carboxylase activity. Soraphen A allosterically inhibits the biotin carboxylase domain of ACC, leading to depletion of malonyl CoA and suppression of fatty acid biosynthesis required for tumor growth. Soraphen A reduces malonyl CoA levels, suppresses fatty acid synthesis, and impairs proliferation of human hepatoma (HepG2) and prostatic cancer (LnCap) cell lines. Its effect is particularly pronounced in cancers with high lipogenic activity, such as prostate and breast cancers. Soraphen A also synergizes with other metabolic inhibitors to enhance anticancer efficacy [85]. in HepG2 and LnCap cells. TOFA Allosteric inhibitor, 5-(Tetradecyloxy)-2-furancarboxylic acid (TOFA) inhibits ACC activity, resulting in reduced malonyl CoA production, impaired lipogenesis, and activation of apoptosis in PDAC cells. It causes pancreatic cancer cells to undergo apoptosis, indicating that ACCA may be a viable target for the creation of new cancer treatment drugs [86]. ND-646 (clinical candidate) ND-646 is a selective ACC1/ACC2 inhibitor developed for clinical applications. ND-646 disrupts ACC dimerization, thereby simultaneously suppressing fatty acid synthesis and altering mitochondrial fatty acid oxidation. Preclinical studies on IDH-1 mutant cancer cell lines and mouse tumor models demonstrated that ND-646 decreases tumor growth in models of non-small cell lung cancer and triple-negative breast cancer, while also enhancing sensitivity to chemotherapy. This dual inhibition of ACC1 and ACC2 suppresses fatty acid synthesis and simultaneously modulates mitochondrial fatty acid oxidation, making it a promising candidate for metabolic therapy in cancer [87] (Fig. 3). Stearoyl CoA desaturase inhibitors CVT-11127 A new small molecule inhibitor of SCD function, CVT-11127, causes SCD1 depletion, which in turn causes decreased lipid synthesis, poor proliferation due to cell cycle arrest at the G1/S transition, and the induction of programmed cell death [88]. Inhibition of SCD1 by CVT-11127 results in decreased monounsaturated fatty acid synthesis, accumulation of saturated fatty acids, induction of ER stress, cell cycle arrest, and apoptosis in cancer cells [62, 89]. A939572 A939572 is a selective small-molecule inhibitor of SCD1 that blocks the desaturation of palmitate and stearate into their monounsaturated counterparts. Preclinical studies on PANC-1, MiaPaCa-2 pancreatic cell lines demonstrated that A939572 reduces cancer cell proliferation, induces apoptosis, and increases sensitivity to chemotherapy. Mechanistically, SCD1 inhibition by A939572 leads to lipid accumulation, endoplasmic reticulum (ER) stress, and ferroptosis in multiple tumor types, including PDAC, lung and breast cancers, highlighting its potential as an anticancer strategy [62, 90]. CAY10566 CAY10566 is another potent SCD1 inhibitor that demonstrates efficacy in reducing MUFA synthesis and tumor cell growth. Studies on ovarian cancer cell lines A2780 and SKOV3 revealed that CAY10566 not only suppresses proliferation but also sensitizes cancer cells to apoptosis induced by chemotherapeutics. In hepatocellular carcinoma and lung cancer models, CAY10566 impaired lipid metabolism, increased ROS levels, and triggered ER stress, emphasizing the multifaceted role of SCD1 inhibition in disrupting cancer cell homeostasis [91]. MF-438 MF-438 is a highly selective SCD1 inhibitor that has shown potent antitumor activity in preclinical models on esophageal squamous cell lines (KYSE70). Inhibition of SCD1 by MF-438 reduces MUFA levels, leading to accumulation of saturated fatty acids, membrane rigidity, lipotoxicity, and apoptosis. Additionally, MF-438 treatment has been reported to interfere with Wnt/β-catenin and PI3K/AKT signaling, further contributing to its anticancer effects [92] (Fig. 3). Acyl CoA synthetases inhibitors Triacsin C Triacsin C inhibits long chain Acyl CoA Synthetases, preventing fatty acid activation. In Human glioma SF268 and U251 cells, Triacsin C selectively induces apoptosis, reduces lipid droplet formation, and suppresses proliferation with limited effect on non-cancerous cells [93]. Mechanistically, Triacsin C blocks the conversion of long chain fatty acids into acyl CoA derivatives, impairing lipid droplet biogenesis, membrane lipid synthesis, and energy metabolism in different types of cancer cells [94]. VY-3–135 (emerging ACS inhibitor) VY-3–135 is a selective inhibitor of ACSL4, which has been linked to ferroptosis sensitivity in cancer cells. Preclinical studies on MDA-MB-231-BrM and 4T1-BrM breast cancer brain metastatic cell models showed that VY-3–135 reduces ACSL4 activity, decreases incorporation of polyunsaturated fatty acids into phospholipids, and triggers ferroptotic cell death in breast and liver cancer models. This highlights ACSL4 as a metabolic vulnerability and positions VY-3–135 as a promising lead for therapeutic development in cancers with high lipid remodeling requirements [95] (Fig. 3). Table 1 summarizes the inhibitors and their mechanisms of action targeting lipogenic enzymes in PDAC. Table 1Illustrates the inhibitors and their mechanisms of action targeting lipogenic enzymes in PDACInhibitorTargetMechanism of actionReferenceCeruleninFASNCovalently binds FASN active site, inhibiting de novo fatty acid synthesis and inducing apoptosis[71]C75FASNInhibits FASN and fatty acid synthesis, activates CPT-1 which increases β-oxidation[72, 73]LuteolinFASNSuppresses FASN mediated lipogenesis and inhibits PI3K/Akt & NF-κB signaling[74]C93FASNInhibits FASN dependent lipid biosynthesis which leads to metabolic stress and apoptosis[75]TVB-2640FASNSelectively inhibits FASN and disrupts membrane lipids and PI3K/AKT/mTOR signaling[76, 77]TVB-3166FASNBlocks intracellular fatty acid synthesis and lipid raft oncogenic signaling[78]OrlistatFASNInhibits thioesterase domain of FASN and suppresses proliferation and induces apoptosis[79, 80]SB-204990ACLYInhibits ACLY mediated conversion of citrate to acetyl CoA as a result suppresses lipogenesis[81, 82]Bempedoic AcidACLYReduces cytosolic acetyl CoA and histone acetylation which inhibits lipid synthesis[83]NDI-091143ACLYSelectively blocks citrate binding site of ACLY which decreases acetyl CoA production[84]Soraphen AACCAllosterically inhibits ACC biotin carboxylase domain and decreases malonyl CoA[85]TOFAACCInhibits ACC activity and reduces malonyl CoA and lipogenesis[86]ND-646ACC1/ACC2Disrupts ACC dimerization and inhibits fatty acid synthesis and alters FA oxidation[87]CVT-11127SCD1Inhibits MUFA synthesis leading to ER stress, cell cycle arrest and apoptosis[88, 89]A939572SCD1Blocks desaturation of palmitate/stearate leading to lipid accumulation and ferroptosis[90]CAY10566SCD1Reduces MUFA synthesis which increases ROS and ER stress[90, 91]MF-438SCD1Decreases MUFA levels leading to membrane rigidity, lipotoxicity and apoptosis[91, 92]Triacsin CACSBlocks conversion of fatty acids into acyl CoA derivatives, impairing lipid droplet biogenesis, membrane lipid synthesis, and energy metabolism in cancer cells[93, 94]VY-3–135ACSL4Inhibits ACSL4, decreases PUFA incorporation into phospholipids and induces ferroptosis[95] Illustrates the inhibitors and their mechanisms of action targeting lipogenic enzymes in PDAC Tumor microenvironment (TME) and fatty acids metabolic reprogramming in PDAC The tumor microenvironment (TME) is a complex, dynamic niche composed of various non-malignant components such as fibroblasts, immune cells, endothelial cells, adipocytes, and extracellular matrix elements. These constituents engage in bidirectional communication with tumor cells, influencing nearly every aspect of cancer biology including proliferation, immune evasion, angiogenesis, and metabolism [96, 97]. A hallmark of the TME is its metabolic harshness tumor regions often suffer from hypoxia, acidosis and limited nutrient availability due to poor vascularization. These conditions apply selective pressure that drives cancer cells to reprogram their metabolism to sustain survival and growth [98]. One key axis of this adaptation is the reprogramming of fatty acid metabolism. In response to nutrient deprivation and hypoxia, cancer cells enhance both de novo lipogenesis and exogenous fatty acid uptake to support energy production, membrane synthesis, and redox balance [99]. Components of the TME actively support this shift. For instance, cancer associated adipocytes (CAAs) release free fatty acids via lipolysis, which are then taken up by adjacent tumor cells through transporters such as CD36 and FATP family members [100]. These fatty acids can be channeled into mitochondrial β-oxidation or stored in lipid droplets, contributing to cancer cell survival under stress. Similarly, tumor associated fibroblasts and immune cells within the TME secrete cytokines and growth factors (e.g., IL-6, TGF-β) that stimulate the activation of lipogenic transcription factors like SREBP1, enhancing fatty acid synthesis in tumor cells [101]. Immune cells and cancer associated fibroblasts (CAFs) are central regulators of fatty acid metabolic reprogramming within the pancreatic tumor microenvironment (TME), and they critically contribute to the establishment of immune suppression in PDAC. Recent evidence highlights that lipid metabolism is not only a tumor intrinsic process but also a dominant driver of immune cell fate and function within the TME, shaping antitumor immunity through extensive metabolic crosstalk between tumor, stromal, and immune compartments [102, 103]. Tumor associated macrophages (TAMs) undergo profound metabolic rewiring in lipid rich environments, characterized by increased fatty acid uptake and enhanced fatty acid oxidation (FAO). This metabolic shift supports M2 like polarization and is associated with elevated expression of CD36, CPT1A, IL-10, and TGF-β, which collectively promote immunosuppression, tissue remodeling, and tumor progression. Importantly, recent studies demonstrate that lipid driven activation of peroxisome proliferator activated receptors (PPAR) and HIF dependent transcriptional programs stabilizes TAM immunosuppressive phenotypes and suppresses cytotoxic immune responses [104, 105]. Similarly, myeloid derived suppressor cells (MDSCs) rely heavily on lipid uptake and FAO for their persistence and suppressive activity in nutrient deprived TMEs. Enhanced lipid metabolism allows MDSCs to maintain redox balance and produce immunosuppressive mediators such as ROS and arginase-1, thereby inhibiting T-cell activation and reinforcing immune escape in PDAC [105]. Cytotoxic CD8⁺ T cells are particularly vulnerable to fatty acid rich microenvironments. Excessive lipid uptake via CD36 leads to mitochondrial dysfunction, lipid peroxidation, and ferroptosis susceptibility, ultimately driving T-cell exhaustion and loss of effector function. Recent mechanistic studies published in 2026 further confirm that lipid overload directly impairs mitochondrial fitness and reinforces immune checkpoint expression (PD-1, TIM-3), contributing to therapy resistance [102, 105]. In contrast, regulatory T cells (Tregs) display enhanced metabolic plasticity and preferentially utilize FAO to sustain survival and suppressive function under glucose deprived conditions. CD36-mediated lipid uptake and CPT1A-driven FAO are essential for maintaining Treg stability and immunosuppressive capacity within the PDAC microenvironment, enabling them to outcompete effector T cells and reinforce immune tolerance [104, 105]. Cancer associated fibroblasts (CAFs) are now recognized as key metabolic orchestrators of immune suppression. A recent study demonstrated that CAFs actively regulate lipid availability within the TME by releasing fatty acids, lactate, and other metabolites, thereby shaping immune cell function and. tumor progression [4]. Inflammatory CAFs (iCAFs) secrete IL-6, CXCL12, and LIF, which promote immune exclusion and enhance tumor lipogenesis through activation of SREBP1 and PI3K/AKT/mTOR signaling pathways. Moreover, CAF derived extracellular matrix remodeling generates a physical barrier that limits immune cell infiltration and exacerbates hypoxia driven metabolic rewiring [103, 106]. Collectively, these findings establish an integrated immunometabolic network in which CAFs, tumor cells, and immune cells cooperate through fatty acid exchange and metabolic competition. This network drives immune suppression, metabolic exhaustion of effector lymphocytes, and resistance to chemotherapy and immunotherapy in PDAC. Importantly, recent 2026 evidence strongly supports that targeting lipid uptake (CD36), FAO (CPT1A), and stromal lipid transfer may restore anti-tumor immunity and improve therapeutic outcomes [102, 105]. Hypoxia further amplifies this metabolic rewiring through the activation of HIF-1α, which upregulates lipid transporters and enzymes involved in lipid droplet formation, allowing cancer cells to accumulate lipid reserves for structural and metabolic flexibility [107]. In addition to glucose and glutamine, acetate has emerged as a critical alternative carbon source for lipid synthesis within the TME, especially under conditions of hypoxia and nutrient scarcity. Cancer cells can scavenge extracellular acetate and convert it into acetyl CoA via acetyl CoA synthetase 2 (ACSS2). This acetyl CoA pool supports both fatty acid biosynthesis and histone acetylation, linking metabolic reprogramming to epigenetic regulation [108, 109]. The expression of ACSS2 is regulated by hypoxic signaling, particularly HIF-2α, enabling tumors to maintain lipogenesis when mitochondrial citrate export is impaired [50] (Fig. 4). This acetate utilization pathway is especially relevant in poorly perfused tumors such as PDAC, where conventional nutrients are limited, and metabolic flexibility becomes essential for survival. Importantly, the metabolic crosstalk between the TME and cancer cells has been linked to therapy resistance. Fatty acid oxidation and lipid storage enhance redox homeostasis and buffer against oxidative damage induced by chemotherapy and radiation [110]. Immunometabolic crosstalk and fatty acid metabolic reprogramming within the pancreatic tumor microenvironment (TME). The pancreatic tumor microenvironment (TME) promotes extensive fatty acid metabolic reprogramming through coordinated interactions among tumor cells, cancer associated fibroblasts (CAFs), adipocytes, and immune cells. Under hypoxic and nutrient deprived conditions, acetate metabolism and glucose derived citrate contribute to acetyl CoA production via ACSS and ACLY, respectively, thereby supporting de novo lipogenesis through ACC, FASN, and SCD pathways. CAF derived cytokines, including IL-6, TGF-β, CXCL12, and LIF, activate SREBP1c and PI3K/AKT/mTOR signaling, enhancing lipid synthesis and stromal remodeling. Immune cells within the TME undergo profound lipid dependent metabolic rewiring. Tumor associated macrophages (TAMs) exhibit increased CD36 mediated fatty acid uptake and CPT1A dependent fatty acid oxidation (FAO), promoting M2 like polarization and secretion of immunosuppressive cytokines such as IL-10 and TGF-β. Similarly, myeloid derived suppressor cells (MDSCs) rely on FAO to sustain reactive oxygen species (ROS), arginase-1, and nitric oxide (NO) production, thereby suppressing T-cell activation. In contrast, excessive lipid uptake in CD8⁺ T- cells induces lipid peroxidation, mitochondrial dysfunction, ferroptosis susceptibility, and T-cell exhaustion characterized by increased PD-1 and TIM-3 expression. Regulatory T cells (Tregs) preferentially utilize FAO to maintain FOXP3 stability and immunosuppressive activity under glucose restricted conditions Clinical challenges and resistance to fatty acid metabolism targeted therapies in PDAC Despite the promising therapeutic potential of targeting fatty acid metabolic reprogramming in PDAC, several challenges continue to limit successful clinical translation. One major obstacle is the profound metabolic heterogeneity and plasticity of PDAC cells, which enables tumors to switch between glycolysis, fatty acid oxidation, glutaminolysis, and other metabolic pathways in response to therapeutic pressure. Consequently, inhibition of a single lipid metabolic enzyme, such as FASN, ACC, or carnitine CPT1, may trigger compensatory metabolic adaptations that reduce therapeutic efficacy and promote drug resistance. In addition, the dense desmoplastic tumor microenvironment characteristic of PDAC impairs drug delivery and contributes to hypoxia, immune suppression, and metabolic crosstalk between cancer cells, cancer associated fibroblasts, adipocytes, and immune cells. These interactions further complicate the response to metabolic inhibitors and may diminish treatment sensitivity. Another important limitation is the potential systemic toxicity associated with targeting lipid metabolism, as fatty acid metabolic pathways are essential for normal cellular homeostasis in tissues such as the liver, skeletal muscle, and immune system. Several inhibitors of fatty acid metabolism have demonstrated encouraging preclinical activity but limited clinical success due to adverse effects, poor pharmacokinetic properties, insufficient tumor selectivity, and inadequate biomarker guided patient stratification. Furthermore, the lack of reliable predictive biomarkers makes it difficult to identify patients who are most likely to benefit from metabolic targeted therapies. Emerging evidence suggests that combining inhibitors of fatty acid metabolism with chemotherapy, immunotherapy, or KRAS targeted therapies may improve therapeutic responses. However, optimal drug combinations, dosing strategies, and treatment timing remain unclear. Therefore, future studies should focus on understanding metabolic adaptation mechanisms, identifying robust biomarkers, improving drug delivery systems, and developing personalized combination strategies to enhance the clinical applicability of fatty acid metabolism targeted therapies in PDAC. Conclusion Lipids play a central role in the progression of pancreatic cancer, serving not only as structural components of cellular membranes but also as key signaling molecules and energy sources. Pancreatic tumor cells undergo extensive metabolic reprogramming, characterized by increased lipid uptake, enhanced de novo lipogenesis, fatty acid oxidation, and lipid storage. These adaptations enable cancer cells to survive and proliferate in the tumor microenvironment, which is often marked by hypoxia, acidosis, and limited nutrient availability. Metabolic reprogramming in pancreatic cancer is driven by both environmental stressors and genetic alterations, including oncogene activation and loss of tumor suppressor function. These changes regulate the expression of lipid metabolizing enzymes, further promoting tumor growth and progression. In addition to tumor cells, immune cells within the pancreatic tumor microenvironment also exhibit altered lipid metabolism. This dysregulation impairs immune cell function, facilitating immune evasion and contributing to tumor invasion and metastasis. Targeting lipid metabolism has emerged as a promising therapeutic strategy in pancreatic cancer. Inhibitors of lipid uptake, lipogenesis, and fatty acid oxidation have demonstrated significant antitumor effects in preclinical and clinical studies. Moreover, modulating lipid metabolism in immune and stromal cells offers an additional avenue to enhance anti-tumor immunity. Combining these approaches with existing treatments, such as chemotherapy and immunotherapy, may improve therapeutic outcomes and provide a more comprehensive strategy for managing pancreatic cancer. Author contributions Bassant Ihab: Writing – original draft. Ekram Saleh: Revision, Editing, Conceptualization &; Supervision. Funding This research received no external funding. Data availability No datasets were generated or analysed during the current study. Declarations Consent to participate All the authors have consented to participate. Consent to publication All the authors have consented to the publication of the text. Competing interests The authors declare no competing interests. Ethics approval This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Bassant Ehab has contributed as first author. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.